A Phase 1-2 Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma

Full Title

ALTITUDE - ALTernating Induction Therapies to achieve Undetectable Disease Endpoints: A Phase 1/2 Alternating Dara-RVd/Teclistamab-RVd in Transplant Eligible Standard-Risk Newly Diagnosed Multiple Myeloma

Purpose

Researchers want to see if Tec-RVd after 3 treatment cycles of Dara-RVd is safe for people with multiple myeloma. The people in this study have newly diagnosed multiple myeloma.

Tec-RVd includes the drugs teclistamab, lenalidomide, bortezomib, and dexamethasone. Dara-RVd includes the drugs daratumumab, lenalidomide, bortezomib, and dexamethasone.

Teclistamab may strengthen the immune system’s ability to fight cancer cells by activating your own cells to destroy your tumor. Daratumumab blocks a protein that can cause tumors to grow. RVd (lenalidomide, bortezomib, and dexamethasone) is a standard treatment for people with newly diagnosed multiple myeloma.

Who Can Join

To join this study, there are a few conditions. You must:

• Have multiple myeloma that has not yet been treated.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Neha Korde’s office at 646-608-3708.